ResultsIQ

ResultsIQ › Latest results › Akums Drugs and Pharmaceuticals Limited

Akums Drugs and Pharmaceuticals Limited Q1 FY26 earnings call summary

NSE: AKUMS · BSE: 544222

Earnings call of 11 Aug 2025, summarised by AI from the filing.

Akums Q1 FY26 total income ₹1,051 cr, up 2.4%, with CDMO growth guided to mid-single-digit for FY26.

Key takeaways

  1. Guidance CDMO revenue growth guided to mid-single-digit for FY26, lowered from mid-to-high single-digit.
  2. Change €100 million received as part consideration for the European contract; cash surplus ₹1,518 cr.
  3. Driver CDMO growth led by better product mix and R&D offerings despite 2.5% API price impact.
  4. Risk API prices declined 10% to 12% in the last 12 months and remain soft.

Original filing on BSE

Akums Drugs and Pharmaceuticals Limited Q1 FY27 results

As filed: Revenue ₹1,167 cr (+14% year on year), EBITDA ₹175 cr (+35% year on year), PAT ₹101 cr (+55% year on year), EBITDA margin 15.0% (+238 bps).

The Q1 FY27 score, against the company's own trend, is for premium members.

Earlier results and the share price after them

  • Q4 FY26: Revenue ₹1,158 cr (+10% year on year), EBITDA ₹152 cr (+61% year on year), PAT ₹81.3 cr (−46% year on year), EBITDA margin 13.1% (+420 bps). Score 49 of 100, In line with trend. EBITDA margin rose 420 bps year on year. Other income 29% of PBT. Not enough history for a trend yet: scored on growth alone. Share price after the results: +15.3% in 29 days (Nifty 500: +1.0%).
  • Q3 FY26: Revenue ₹1,160 cr (+15% year on year), EBITDA ₹147 cr (+21% year on year), PAT ₹67.7 cr (+37% year on year), EBITDA margin 12.7% (+68 bps). Score 53 of 100, In line with trend. EBITDA margin rose 68 bps year on year. Other income 34% of PBT. Consolidated profit +3% but standalone -31%. Not enough history for a trend yet: scored on growth alone. Share price after the results: +6.6% in 30 days (Nifty 500: −1.1%).
  • Q2 FY26: Revenue ₹1,018 cr (−1% year on year), EBITDA ₹95.0 cr (−22% year on year), PAT ₹43.0 cr (−36% year on year), EBITDA margin 9.3% (−248 bps). Score 7 of 100, Below trend. EBITDA margin fell 248 bps year on year. Other income 48% of PBT. Not enough history for a trend yet: scored on growth alone. Profit fell 34% from last quarter. Share price after the results: −3.3% in 29 days (Nifty 500: −0.4%).
  • Q1 FY26: Revenue ₹1,024 cr (0% year on year), EBITDA ₹129 cr (+2% year on year), PAT ₹65.0 cr (+7% year on year), EBITDA margin 12.6% (+13 bps). Score 28 of 100, Below trend. EBITDA margin rose 13 bps year on year. Other income 28% of PBT. Not enough history for a trend yet: scored on growth alone. Revenue fell 3% from last quarter. Share price after the results: −4.2% in 28 days (Nifty 500: +1.7%).
  • Q4 FY25: Revenue ₹1,056 cr, EBITDA ₹94.0 cr, PAT ₹150 cr, EBITDA margin 8.9%. Not scored. No consolidated results for the same quarter last year to compare yet (consolidated revenue ₹1,056 cr). Scored once a year-earlier consolidated quarter exists. Share price after the results: −1.1% in 30 days (Nifty 500: +1.7%).
  • Q3 FY25: Revenue ₹1,010 cr, EBITDA ₹121 cr, PAT ₹66.0 cr, EBITDA margin 12.0%. Not scored. No consolidated results for the same quarter last year to compare yet (consolidated revenue ₹1,010 cr). Scored once a year-earlier consolidated quarter exists.
  • Q2 FY25: Revenue ₹1,033 cr, EBITDA ₹122 cr, PAT ₹67.0 cr, EBITDA margin 11.8%. Not scored. No consolidated results for the same quarter last year to compare yet (consolidated revenue ₹1,033 cr). Scored once a year-earlier consolidated quarter exists.

Past price moves after results do not indicate future moves. Not a recommendation.

Akums Drugs and Pharmaceuticals Limited earnings call, investor presentation and press release summaries

Figures from the company's filings with NSE and BSE. Not investment advice.